IRIS
BRAVACCINI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.461
AS - Asia 1.449
EU - Europa 744
SA - Sud America 547
AF - Africa 33
OC - Oceania 2
Totale 5.236
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.408
SG - Singapore 702
BR - Brasile 485
HK - Hong Kong 391
IE - Irlanda 311
VN - Vietnam 126
IT - Italia 103
DE - Germania 91
CN - Cina 55
TR - Turchia 54
FR - Francia 43
NL - Olanda 34
GB - Regno Unito 32
BD - Bangladesh 30
AR - Argentina 27
FI - Finlandia 26
IN - India 25
MX - Messico 25
CA - Canada 24
RU - Federazione Russa 22
AT - Austria 16
IQ - Iraq 16
LT - Lituania 11
UA - Ucraina 11
CO - Colombia 9
PK - Pakistan 9
PL - Polonia 9
ZA - Sudafrica 9
ES - Italia 8
TN - Tunisia 8
BE - Belgio 6
CZ - Repubblica Ceca 6
EC - Ecuador 6
EG - Egitto 6
ID - Indonesia 6
JP - Giappone 6
UZ - Uzbekistan 6
CL - Cile 5
PY - Paraguay 5
SA - Arabia Saudita 5
SE - Svezia 5
VE - Venezuela 5
SN - Senegal 4
AZ - Azerbaigian 3
IL - Israele 3
MA - Marocco 3
UY - Uruguay 3
AL - Albania 2
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
KE - Kenya 2
KG - Kirghizistan 2
LB - Libano 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
TT - Trinidad e Tobago 1
Totale 5.236
Salva come PNG Salva come JPEG
Città #
Dallas 1.333
Hong Kong 389
Singapore 375
Dublin 311
San Jose 200
Ashburn 185
Santa Clara 138
Boardman 136
The Dalles 134
Ho Chi Minh City 47
São Paulo 47
Istanbul 43
Munich 38
Assago 32
Amsterdam 23
Helsinki 23
Rio de Janeiro 22
Beijing 20
Hanoi 20
Los Angeles 18
Frankfurt am Main 17
Brasília 12
Belo Horizonte 10
Boston 10
Chicago 10
Milan 10
Vienna 10
Düsseldorf 9
Haiphong 9
Montreal 9
New York 9
Porto Alegre 9
San Francisco 9
Brooklyn 7
Campinas 7
Mexico City 7
Warsaw 7
Ankara 6
Bexley 6
Brno 6
Brussels 6
Buenos Aires 6
Guarulhos 6
Paris 6
Salvador 6
Tokyo 6
Toronto 6
Atlanta 5
Chennai 5
Lahore 5
Lugo 5
Manchester 5
Nuremberg 5
Quito 5
Stockholm 5
Tashkent 5
Thái Bình 5
Asunción 4
Bogotá 4
Contagem 4
Curitiba 4
Dakar 4
Dhaka 4
Hải Dương 4
Juiz de Fora 4
New Delhi 4
Ottawa 4
Piracicaba 4
Ribeirão Preto 4
Riyadh 4
Rome 4
Roubaix 4
Sorocaba 4
Teresina 4
Atibaia 3
Baku 3
Betim 3
Birmingham 3
Biên Hòa 3
Cairo 3
Cape Town 3
Da Nang 3
Denver 3
Erbil 3
Hillsboro 3
Hortolândia 3
Houston 3
Itaquaquecetuba 3
Johannesburg 3
João Pessoa 3
Lauterbourg 3
Limeira 3
London 3
Maceió 3
Maricá 3
Milwaukee 3
Montevideo 3
Nova Iguaçu 3
Osasco 3
Palhoça 3
Totale 3.951
Salva come PNG Salva come JPEG
Nome #
The current status of biomarkers for bladder cancer: progress and challenges 139
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 85
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy. 83
Expanding the Horizon of Multidisciplinarity: Incorporating Biomechanical, Metabolic, and Functional Factors Into Registry-Based Research to Predict Subsequent Risk for Total Knee Arthroplasty 72
Biomarkers: which ones do we really need today? 68
Re: Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer 62
The use of platelets as a clinical tool in oncology: opportunities and challenges 61
Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study 60
A functional survey of the regulatory landscape of estrogen-receptor-positive breast cancer evolution 60
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 60
A Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors 56
Knee pain and gait alterations: bridging physiology, biomechanics, and clinical practice 55
Decoding the NRF2–NOTCH Crosstalk in Lung Cancer—An Update 54
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 53
Androgen receptor signaling pathways as a target for breast cancer treatment 52
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 49
Fluorescence In Situ Hybridization in Urine Samples (UroVysion Kit) 49
An initiative to assess the quality of Tanzanian cervical cancer specimens for HPV and telomerase detection 48
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma insitu treated with surgery and radiotherapy 48
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 48
Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer 48
Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota 47
FAP inhibitors: are we really using the best method to evaluate the residence time? 47
Urinary Biomarkers in Tumors: An Overview 47
Letter to the Editor discussing: Hacker S, Lenz C, Reichert L, Ringseis R, Zentgraf K, Krüger K. Vitamin D status and its determinants in German elite athletes. Eur J Appl Physiol. 2025 Jan 4. doi: 10.1007/s00421-024–05699-6 46
Are Androgen and Estrogen Receptors in DCIS Patients Prognostic Indicators of Relapse Independently of Treatment? 46
An H-1 NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia 46
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 46
Androgen receptor in breast cancer: The "5W" questions 46
Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients 45
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 44
Evaluating the appropriateness of chemotherapy in a low-resource cancer centre in sub-Saharan Africa 43
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 43
Telomerase Activity Analysis In Urine Sediment for Bladder Cancer 43
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer? 43
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 42
Combining preclinical tools and models to unravel tumor complexity: Jump into the next dimension 42
Are we ready to use TMB in breast cancer clinical practice? 42
ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA 42
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 42
Urinary biomarkers of nonmuscle-invasive bladder cancer: current status and future potential 42
Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy 42
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in patients with different subtypes of breast cancer 41
Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer 41
Exploring the Relationship Between Humoral and Cellular T Cell Responses Against SARS-CoV-2 in Exposed Individuals From Emilia Romagna Region and COVID-19 Severity 41
Explaining the aggressiveness of breast cancer in sub-Saharan African patients 41
Microenvironmental determinants of cancer progression during obesity: emerging evidence and novel perspectives 41
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial 40
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 40
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study 40
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 40
ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients 40
Usefulness of immunological detection of the human telomerase reverse transcriptase 39
Are fine-needle aspiration biopsy-derived cell blocks a useful surrogate for tissue samples in breast cancer? 39
TMB in NSCLC: A Broken Dream? 38
What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia? 38
Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR) 38
Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance 38
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 38
Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients. 38
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 37
Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells 37
Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR) 37
In-111-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance 36
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report 36
Significant Advancements and Evolutions in Chimeric Antigen Receptor Design 36
Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study 36
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease. 36
Why the complications of COVID-19 patients differ in elderly and young cancer patients 36
TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer 36
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 35
Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer" 35
Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma 35
New Biomarkers to Predict the Evolution of In Situ Breast Cancers 35
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 34
Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data 34
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression 34
Expanding Roles of De Novo Lipogenesis in Breast Cancer 33
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 33
Relevance of urine telomerase in the diagnosis of bladder cancer 33
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer 32
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 32
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis 32
The current status of biomarkers for bladder cancer: progress and challenges 32
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer 32
Human papillomavirus E6 alters Toll-like receptor 9 transcripts and chemotherapy responses in breast cancer cells in vitro 32
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 32
Urine telomerase: An important marker in the diagnosis of bladder cancer 31
Spotlight on PSMA as a new theranostic biomarker for bladder cancer 31
What to look for in cell-free DNA from breast cancer patients 31
Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients 31
Unraveling the protein kinase C/NDRG1 signaling network in breast cancer. 31
Erratum to: Benefit from anthracyclines in relation to biological profiles in early breast cancer 31
Setting Up a Medical Oncology Educational Program in Sub-Saharan Africa 30
Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls 30
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer A case report 30
No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country 30
Predictive role of telomerase activity in the clinical outcome of patients with benign lesions of the uterine cervix or CIN 30
Urine telomerase activity for the detection of bladder cancer in females 30
Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold 30
Totale 4.271
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.956
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024187 0 0 0 0 0 0 0 0 0 0 0 187
2024/20252.496 264 71 193 57 234 318 149 135 304 299 283 189
2025/20262.814 313 965 545 415 150 167 259 0 0 0 0 0
Totale 5.497